Pfizer (NYSE:PFE) Shares Gap Down – Time to Sell?

Shares of Pfizer Inc. (NYSE:PFE) gapped down before the market opened on Tuesday . The stock had previously closed at $26.66, but opened at $25.36. Pfizer shares last traded at $25.7460, with a volume of 15,210,619 shares trading hands.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat — Pfizer reported revenue of $17.56B and adjusted EPS of $0.69, both above consensus, which sparked initial buying and renewed confidence in near‑term fundamentals. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: GLP‑1 clinical win — The Phase 2b VESPER‑3 readout for MET‑097i showed up to ~12.3% placebo‑adjusted weight loss at 28 weeks and sustained losses after switching to monthly dosing, supporting Pfizer’s entry into the growing obesity/GLP‑1 market. Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss
• Positive Sentiment: Longer‑term growth story — MarketBeat and others highlight an underappreciated oncology + AI upside (Seagen assets, ~60 pipeline candidates, AI partnerships and internal platforms) that could drive durable revenue expansion and R&D efficiency gains. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Neutral Sentiment: FY‑2026 guidance = mixed signal — Pfizer set EPS guidance of $2.80–3.00 and revenue $59.5B–$62.5B (consensus nearer ~$2.97 EPS and $60.9B revenue), a modest miss at midpoint that tempers enthusiasm until cadence of future quarters is clear. Pfizer (PFE) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst stance is cautious — Several firms (Cantor Fitzgerald, Citi, others) are keeping neutral/hold ratings and modest price targets (~$26–$27), signaling limited near‑term upside without clearer commercial readouts. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Competitive and program‑risk headwinds — Market reaction was mixed as investors weigh how quickly Pfizer can take meaningful share from entrenched GLP‑1 leaders (Eli Lilly, Novo Nordisk); there’s also the recent program reshuffle with BioNTech on modRNA shingles that underscores pipeline uncertainty. Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? Balanced Near-Term Pipeline Upside Versus Structural Profit Headwinds Keeps Pfizer at Hold

Analyst Upgrades and Downgrades

PFE has been the subject of several research reports. HSBC restated a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Bank of America decreased their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Zacks Research downgraded Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.06.

Pfizer Price Performance

The company has a market cap of $150.60 billion, a PE ratio of 19.48 and a beta of 0.47. The stock has a fifty day moving average price of $25.57 and a 200-day moving average price of $25.07. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period in the previous year, the firm earned $0.63 earnings per share. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. State Street Corp increased its holdings in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after buying an additional 2,786,098 shares during the last quarter. Geode Capital Management LLC raised its position in Pfizer by 1.4% during the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after acquiring an additional 1,820,634 shares in the last quarter. Norges Bank acquired a new stake in Pfizer in the second quarter valued at approximately $2,270,157,000. Finally, Northern Trust Corp grew its position in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after acquiring an additional 869,175 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.